China’s Hengrui posts 89% rise in third-quarter net profit, beating estimates

LongbridgeAII'm LongbridgeAI, I can summarize articles.
Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, reported a 20.55 per cent rise in third-quarter revenue to 8.95 billion yuan (US$1.34 billion), beating analyst estimates of 8.55 billion yuan amid stronger innovative drug sales. Net profit reached 2.46 billion yuan for the three months ended September 30, jumping 88.92 per cent year on year and exceeding the Bloomberg analyst consensus estimate of 2.38 billion yuan. Improving innovative drug sales and out-licensing revenue contributed to the growth, the company said in a Tuesday filing. The stronger quarter helped Hengrui recover from a disappointing first half, when revenue declined 1.9 per cent year on year to 15.5 billion yuan, and net profit edged up just 0.3 per cent to 4.47 billion yuan. Revenue for the first nine months of the year reached 24.4 billion yuan, up 5.26 per cent year on year, while net profit for the first three quarters also grew 20.38 per cent to 6.92 billion yuan. Hengrui’s Hong Kong-listed shares fell 5.13 per cent ahead of its earnings release. The company attributed its first-half revenue decline to China’s national and regional centralised procurement policies, which aim to lower medicine prices through bulk purchasing. Generic medicine sales plunged 16.1 per cent year on year for the six months ended June 30, the company said. In August, the company said that it had “proactively” scaled back resources allocated to its generic medicine business to limit related risks. On Tuesday, Hengrui said its generic drug business had continued to decline while sales from innovative medicines maintained steady growth. First-half sales of innovative drugs jumped 16.4 per cent year on year to 8.8 billion yuan. For the nine months ended September 30, innovative medicines generated 13.87 billion yuan in revenue, up 17.05 per cent year on year and accounting for 64.59 per cent of total drug sales, compared with 61.69 per cent in the first quarter. Even so, growth in innovative drug revenue so far this year had fallen short of the company’s expectations at the beginning of the year, Hengrui said, citing “slower-than-expected progress in hospital access” and intensifying competition. Licensing deals with global pharmaceutical companies had given its performance a boost, the company noted in its Tuesday filing. Out-licensing revenue jumped 31.12 per cent from a year ago to 2.78 billion yuan. Earlier this month, Hengrui entered into a major licensing deal with Danish pharmaceutical giant Novo involving the Chinese company’s oral GLP-1 weight-loss drug HRS-1596. The agreement is worth up to US$2.6 billion, including a US$300 million upfront payment. The Chinese pharmaceutical giant, which has one of the largest oncology drug pipelines among domestic drug makers, has also stepped up efforts in areas including immunology and weight management. Its psoriasis drug SHR-1139 is currently undergoing phase-two trials and had shown “impressive” results, JP Morgan analysts including Yang Huang wrote in a note earlier this month. Planned phase-three trials could give it “potential domestic leadership and broader international relevance”, the analysts said. Hengrui’s results came a day after strong earnings from WuXi AppTec, a contract research and manufacturing giant, underscoring the momentum among Chinese biotech firms. WuXi AppTec raised its full-year revenue guidance after net profit surged 62.4 per cent in the first nine months of 2026 and revenue increased 38.6 per cent, driven by strong demand for drug development and manufacturing services. On Tuesday, CCB International analyst Jason Siu wrote in a note that the company had benefited from “strong global demand” for both GLP-1 obesity drugs and outsourcing services in China as global drug makers sought high-quality, cheaper, innovative medicines and services.

Source: SCMP The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.